(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/054828 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/4365* (2006.01)
C07D 498/04 (2006.01) *A61K 31/437* (2006.01)
C07D 513/04 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4355 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2010/066659

(22) International Filing Date:
2 November 2010 (02.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2678/CHE/2009 4 November 2009 (04.11.2009) IN

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOCK, Mark G.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **CHIKKANNA, Dinesh** [IN/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore, Karnataka 560 100 (IN). **MCCARTHY, Clive** [GB/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **MOEBITZ, Henrik** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **PANDIT, Chetan** [CA/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore, Karnataka 560 100 (IN).

(74) Agent: **STRANG, Andrea**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS



(IA)

(57) Abstract: The present invention relates to compounds of Formula (IA) Where R^{1a}, R^{1b}, X, R^{2a}, R^{2b}, W, R^3, R^4, and R^5 are as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.

WO 2011/054828 A1